Ignite Creation Date:
2024-05-06 @ 5:59 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05509478
Status:
UNKNOWN
Last Update Posted:
2022-09-10
First Post:
2022-08-18
Brief Title:
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for UnresectableAdvanced Biliary Tract Carcinoma
Sponsor:
The First Hospital of Jilin University
Organization:
The First Hospital of Jilin University
Study Overview
Official Title:
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for UnresectableAdvanced Biliary Tract Carcinomaa MulticenterSingle-armPhase II Study
Status:
UNKNOWN
Status Verified Date:
2022-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LEADER-001
Brief Summary:
This is a multi-center single-armphase Ⅱ study to evaluate the efficacy and safety of Lenvatinib in combination with PD-1 inhibitors as first-line treatment in patients with unresectable advanced Biliary Tract Carcinoma BTC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None